ATE374178T1 - 2-alkylidene-19-nor-vitamin d verbindungen und ihre therapeutische verwendungen - Google Patents

2-alkylidene-19-nor-vitamin d verbindungen und ihre therapeutische verwendungen

Info

Publication number
ATE374178T1
ATE374178T1 AT01920897T AT01920897T ATE374178T1 AT E374178 T1 ATE374178 T1 AT E374178T1 AT 01920897 T AT01920897 T AT 01920897T AT 01920897 T AT01920897 T AT 01920897T AT E374178 T1 ATE374178 T1 AT E374178T1
Authority
AT
Austria
Prior art keywords
compounds
vitamin
group
diseases
alkylidene
Prior art date
Application number
AT01920897T
Other languages
English (en)
Inventor
Hector Deluca
Rafal Sicinski
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of ATE374178T1 publication Critical patent/ATE374178T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01920897T 2000-03-31 2001-03-29 2-alkylidene-19-nor-vitamin d verbindungen und ihre therapeutische verwendungen ATE374178T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/540,686 US6392071B1 (en) 1997-03-17 2000-03-31 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds

Publications (1)

Publication Number Publication Date
ATE374178T1 true ATE374178T1 (de) 2007-10-15

Family

ID=24156520

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01920897T ATE374178T1 (de) 2000-03-31 2001-03-29 2-alkylidene-19-nor-vitamin d verbindungen und ihre therapeutische verwendungen

Country Status (14)

Country Link
US (5) US6392071B1 (de)
EP (1) EP1268416B1 (de)
JP (1) JP4022071B2 (de)
KR (1) KR20020091167A (de)
AT (1) ATE374178T1 (de)
AU (2) AU4790501A (de)
CA (1) CA2404548C (de)
DE (1) DE60130640T2 (de)
DK (1) DK1268416T3 (de)
ES (1) ES2291305T3 (de)
IL (1) IL152020A (de)
MX (1) MXPA02009590A (de)
NZ (1) NZ522160A (de)
WO (1) WO2001074766A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
EP1453798B1 (de) * 2001-12-13 2008-10-15 Wisconsin Alumni Research Foundation (20s)-1 alpha-hydroxy-2-methylen-19-nor-bishomopregnacalciferol und ihre verwendungen
US6627622B2 (en) 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US20030195175A1 (en) * 2002-03-25 2003-10-16 Deluca Hector F. Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
EP1559708A4 (de) * 2002-10-10 2006-07-19 Wisconsin Alumni Res Found 2,2-disubstituiertes 1a,25-dihydroxy-19-norvitamin-d-derivat
WO2004076468A1 (ja) 2003-02-25 2004-09-10 Kobe Tennenbutsu Kagaku Kabushiki Kaisha ビタミンd誘導体を合成するための新規な中間体
ZA200506204B (en) * 2003-04-10 2006-10-25 Wisconsin Alumni Res Found 2-propylidene-19-nor-vitamin D compounds
EP1677802A2 (de) * 2003-04-30 2006-07-12 Bioxell S.p.a. 1,3 acylierte 24-keto-vitamin d3 verbindungen und anwendungsverfahren dafür
ATE350043T1 (de) * 2003-07-03 2007-01-15 Wisconsin Alumni Res Found 2-methylen-19-nor-20(s)-25-methyl-1alpha- hydroxycalciferol und seine verwendungen
US6894037B2 (en) * 2003-07-03 2005-05-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses
US20050009792A1 (en) * 2003-07-08 2005-01-13 Deluca Hector F. (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses
US7232810B2 (en) * 2003-08-20 2007-06-19 Wisconsin Alumni Research Foundation 2-methylene-19-nor-vitamin D2 compounds
WO2005027916A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and aromatase inhibitors
WO2005027928A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vit amin d derivatives for the treatment of hypocalcemic tetany or hyproparathyroidism
WO2005027918A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a cyclooxgenase-2 inhibitor
EP1667692A1 (de) * 2003-09-19 2006-06-14 Pfizer Products Inc. Pharmazeutische zusammensetzungen mit kombinationen von 2-alkyliden-19-nor-vitamin d derivaten und einem östrogen-agonisten/antagonisten
WO2005027922A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of hypogonadism or andropause
US7214670B2 (en) * 2003-09-24 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 to increase the life expectancy of human beings
US7704980B2 (en) * 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US7053075B2 (en) * 2003-11-25 2006-05-30 Deluca Hector F Methods for reducing body fat using vitamin D compounds
JP2007512376A (ja) * 2003-11-25 2007-05-17 ウイスコンシン アラムニ リサーチ ファンデーション 肥満症の予防及び治療用ビタミンd類似体
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
US7915242B2 (en) * 2004-02-17 2011-03-29 Wisconsin Alumni Research Foundation Vitamin D receptor antagonists and their use in treating asthma
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
EP1812011A1 (de) 2004-11-12 2007-08-01 Bioxell S.p.a. Kombinierte verwendung von vitamin-d-derivaten und antiproliferativen mitteln zur behandlung von blasenkrebs
JP2008520708A (ja) * 2004-11-22 2008-06-19 ウイスコンシン アラムニ リサーチ ファンデーション 2−メチレン−19−ノル−(20R)−1α−ヒドロキシ−ビスホモプレグナカルシフェロール
AU2005309791A1 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2-methylene-19,26,27-trinor-(20S)-1alpha-hydroxyvitamin D3 and its uses
WO2006057915A2 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol
CA2588410C (en) * 2004-11-22 2013-04-02 Wisconsin Alumni Research Foundation 2-methylene-19-nor-1.alpha.-hydroxy-17-ene-homopregnacalciferol and its uses
CA2588060A1 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20s)-1alpha-hydroxy-trishomopregnacalciferol
ES2404061T3 (es) * 2005-02-11 2013-05-23 Wisconsin Alumni Research Foundation 2-Metileno-19-nor-(20S-24S)-1-alfa,25-dihidroxivitamina-D2
MX2007009725A (es) * 2005-02-11 2007-09-26 Wisconsin Alumni Res Found 2-metilen-19-nor-(20s-24epi)-1a, 25-dihidroxivitamina-d2.
JP2008538214A (ja) * 2005-03-29 2008-10-16 ウイスコンシン アラムニ リサーチ ファンデーション 2−メチレン−19−ノル−(23S)−25−デヒドロ−1α−ヒドロキシビタミンD3−26,23−ラクトンおよび2−メチレン−19−ノル−(23R)−25−デヒドロ−1α−ヒドロキシビタミンD3−26,23−ラクトン
WO2006119309A2 (en) * 2005-05-03 2006-11-09 Wisconsin Alumni Research Foundation 19,26,27-TRINOR-1α,25-DIHYDROXYVITAMIN D3 COMPOUNDS
CA2620354C (en) 2005-08-30 2013-02-05 Wisconsin Alumni Research Foundation Des-c,d analogs of 1.alpha.,25-dihydroxy-19-norvitamin d3
US7803789B2 (en) 2006-02-02 2010-09-28 Wisconsin Alumni Research Foundation Vitamin D analog—RAK, methods and uses thereof
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
EP2010483A2 (de) * 2006-04-05 2009-01-07 Wisconsin Alumni Research Foundation 1.alpha.-hydroxy-2-(3'-hydroxypropyliden)-19-nor-vitamin-d-verbindungen sowie verfahren zu ihrer herstellung und verwendung
US20090281340A1 (en) * 2006-04-05 2009-11-12 Deluca Hector F 1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and treatment thereof
EP2001841B1 (de) * 2006-04-06 2012-06-13 Wisconsin Alumni Research Foundation 2-methylen-1-alpha-hydroxy-18,19,21-trinorvitamin-d3-analoge und deren verwendungen
AU2007349772A1 (en) * 2006-04-06 2008-10-23 Wisconsin Alumni Research Foundation 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin D3 and uses thereof
AU2007298652A1 (en) * 2006-04-06 2008-03-27 Wisconsin Alumni Research Foundation 2-methylene-1alpha-hydroxy-19,21-dinorvitamin D3 analogs and uses thereof
CA2647981A1 (en) * 2006-04-06 2008-03-06 Wisconsin Alumni Research Foundation 19-nor-vitamin d analogs with 1,2,or 3,2 heterocyclic ring
US7648973B2 (en) * 2006-04-06 2010-01-19 Wisconsin Alumni Research Foundation 2-methylene-1α,25-dihydroxy-19,21-dinorvitamin D3 analogs and uses thereof
EP2021320A2 (de) 2006-04-06 2009-02-11 Wisconsin Alumni Research Foundation 2-substituierte 1-alpha-25-dihydroxy-19,26,27-trinor-vitamin-d-analoge und deren anwendungen
DE602007012216D1 (de) * 2006-04-10 2011-03-10 Wisconsin Alumni Res Found 1-alpha-hydroxy-2-(3'-hydroxypropyliden)-19-nor-vitamin-d-verbindungen mit einer 1,1-dimethylpropyl-seitenkette
US20080171728A1 (en) * 2007-01-12 2008-07-17 Quatrx Pharmaceuticals Co. Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone
US8377913B2 (en) * 2007-11-20 2013-02-19 Abbvie Inc. Vitamin D receptor activators and methods of making
AU2009206449B2 (en) * 2008-01-22 2014-04-24 Wisconsin Alumni Research Foundation 13,13-Dimethyl-des-C,D analogs of 1alpha, 25-dihydroxy-19-nor-vitamin D3 compounds and topical composition dosage forms and methods of treating skin conditions
CA2715811A1 (en) * 2008-03-06 2009-09-11 Wisconsin Alumni Research Foundation Methods of increasing epidermal skin thickness by topical administration of a 19-nor containing vitamin d compound
US7888339B2 (en) * 2008-07-10 2011-02-15 Wisconsin Alumni Research Foundation 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
US7893043B2 (en) * 2008-07-10 2011-02-22 Wisconsin Alumni Research Foundation 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs
US8222236B2 (en) * 2008-07-10 2012-07-17 Wisconsin Alumni Research Foundation 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs
SG173119A1 (en) 2009-01-27 2011-08-29 Berg Biosystems Llc Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
EP3603646B1 (de) 2009-08-14 2024-04-03 BPGbio, Inc. Vitamin d3 und analoge davon zur behandlung von alopezie
US8217023B2 (en) 2009-10-02 2012-07-10 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 1,2- or 3,2-cyclopentene ring
NZ599216A (en) * 2009-10-02 2014-01-31 Wisconsin Alumni Res Found 1-desoxy-2-methylene-19-nor-vitamin d analogs and their uses
EP2490695B1 (de) * 2009-10-21 2013-11-20 Wisconsin Alumni Research Foundation Verfahren zur vorbeugung der diabetes typ i
JP5931845B2 (ja) * 2010-03-23 2016-06-08 ウイスコンシン アラムニ リサーチ ファンデーション 2−メチレン−19−ノル−22−メチル−1α,25−ジヒドロキシビタミンD3のジアステレオマー
JP5770261B2 (ja) * 2010-03-23 2015-08-26 ウイスコンシン アラムニ リサーチ ファンデーション (20S)−2−メチレン−19−ノル−22−ジメチル−1α,25−ジヒドロキシビタミンD3および(20R)−2−メチレン−19−ノル−22−ジメチル−1α,25−ヒドロキシビタミンD3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
WO2012166938A2 (en) 2011-06-03 2012-12-06 Wisconsin Alumni Research Foundation (22e)-2-methylene-26,27-cyclo-22-dehydro-1alpha-hydroxy-19-norvitamin d3 derivatives
EP2721004B1 (de) 2011-06-14 2017-07-26 Wisconsin Alumni Research Foundation 3-desoxy-2-methylen-19-nor-vitamin-d-analoga und ihre verwendung
US8410080B1 (en) 2011-10-21 2013-04-02 Wisconsin Alumni Research Foundation 2-methylene-vitamin D analogs and their uses
US8455467B2 (en) 2011-10-21 2013-06-04 Wisconsin Alumni Research Foundation 2-methylene-vitamin D analogs and their uses
US20130295083A1 (en) * 2012-05-02 2013-11-07 Wisconsin Alumni Research Foundation 2a-Methyl-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2AMD) or 2 methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2MD) Support Survival and Function of Transplanted Islet Cells In Type 1 Diabetes
US8785422B2 (en) 2012-06-06 2014-07-22 Wisconsin Alumni Research Foundation A-ring modified 19-nor-vitamin D analogs and their uses
CN112156097A (zh) 2013-05-29 2021-01-01 博格有限责任公司 使用维生素d预防或减轻化疗诱发的脱发

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3276167D1 (en) 1981-11-02 1987-06-04 Res Inst Medicine Chem Intermediates in the synthesis of vitamin d derivatives
US4666634A (en) 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
US4800198A (en) * 1985-04-23 1989-01-24 Wisconsin Alumni Research Foundation Method of inducing the differentiation of malignant cells with secosterol
US4851401A (en) 1988-07-14 1989-07-25 Wisconsin Alumni Research Foundation Novel cyclopentano-vitamin D analogs
GB8904154D0 (en) 1989-02-23 1989-04-05 Leo Pharm Prod Ltd Chemical compounds
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
NZ232734A (en) 1989-03-09 1991-11-26 Wisconsin Alumni Res Found 19-nor vitamin d derivatives and pharmaceutical compositions
AU649057B2 (en) 1990-08-24 1994-05-12 Wisconsin Alumni Research Foundation Methods and compositions containing vitamin D compounds for improvement of skin conditions
DK0474517T3 (da) 1990-09-07 1999-08-02 Wisconsin Alumni Res Found Hidtil ukendt anvendelse af 1alfa-hydroxyleret-19-nor-vitamin D-
US5089641A (en) * 1991-03-11 1992-02-18 Wisconsin Alumni Research Foundation Synthesis of 1α-hydroxy-secosterol compounds
US5086191A (en) 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
AU650751B2 (en) 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
ZA924811B (en) 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
JP2898882B2 (ja) 1993-04-05 1999-06-02 ウイスコンシン アラムナイ リサーチ フオンデーシヨン 2−位に置換基を有する19−ノル−ビタミンd3 化合物
WO1996001811A1 (en) 1994-07-11 1996-01-25 The Johns-Hopkins University 2-substituted 1,25-dihydroxyvitamin d3 derivatives
WO1996016035A1 (en) 1994-11-21 1996-05-30 Wisconsin Alumni Research Foundation 18,19-dinor-vitamin d compounds
US5877168A (en) 1995-02-10 1999-03-02 Chugai Seiyaku Kabushiki Kaisha Vitamin D derivative with substituent at the 2β-position
IL118156A (en) 1995-05-09 2001-08-26 Duphar Int Res Vitamin d compounds, their preparation and pharmaceutical compositions containing them
JP3344726B2 (ja) 1995-06-06 2002-11-18 メルク エンド カンパニー インコーポレーテッド 無水アレンドロネート一ナトリウム塩製剤
WO1997000242A1 (de) * 1995-06-14 1997-01-03 Schering Aktiengesellschaft Neue vitamin d-derivate mit substituenten an c-25, verfahren zu ihrer herstellung, zwischenprodukte und die verwendung zur herstellung von arzneimitteln
US6566351B1 (en) * 1995-12-28 2003-05-20 Chugai Seiyaku Kabushiki Kaisha Malignant tumor metastasis inhibitors
US5849960A (en) * 1996-11-26 1998-12-15 Shell Oil Company Highly branched primary alcohol compositions, and biodegradable detergents made therefrom
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US6573256B2 (en) * 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US5945410A (en) 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US6306844B1 (en) * 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US5936105A (en) 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
US6114317A (en) * 1998-05-21 2000-09-05 Wisconsin Alumni Research Foundation Method of locking 1α-OH of vitamin D compounds in axial orientation
US5972917A (en) * 1998-05-29 1999-10-26 Bone Care Int Inc 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof
US5962707A (en) 1998-08-18 1999-10-05 Wisconsin Alumni Research Foundation 19-nor-vitamin D3 compounds with calcemic activity
AU2001265272B2 (en) * 2000-05-31 2006-08-17 Wisconsin Alumni Research Foundation 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds
DE60105035T2 (de) * 2000-09-08 2005-08-18 Wisconsin Alumni Research Foundation, Madison 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol und seine therapeutische verwendungen
US6627622B2 (en) * 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6835723B2 (en) * 2001-12-13 2004-12-28 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-1α-hydroxy-bis-homo-pregnacalciferol in crystalline form
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses

Also Published As

Publication number Publication date
MXPA02009590A (es) 2004-03-26
AU4790501A (en) 2001-10-15
WO2001074766A1 (en) 2001-10-11
KR20020091167A (ko) 2002-12-05
IL152020A (en) 2008-03-20
US20090143342A1 (en) 2009-06-04
JP4022071B2 (ja) 2007-12-12
EP1268416A1 (de) 2003-01-02
US20030181427A1 (en) 2003-09-25
US7094774B2 (en) 2006-08-22
CA2404548C (en) 2009-07-21
US6537981B2 (en) 2003-03-25
DK1268416T3 (da) 2008-02-04
EP1268416B1 (de) 2007-09-26
AU2001247905B2 (en) 2005-05-19
CA2404548A1 (en) 2001-10-11
ES2291305T3 (es) 2008-03-01
JP2003529581A (ja) 2003-10-07
DE60130640T2 (de) 2008-07-17
US20040167104A1 (en) 2004-08-26
US6392071B1 (en) 2002-05-21
US20020087015A1 (en) 2002-07-04
NZ522160A (en) 2004-11-26
DE60130640D1 (de) 2007-11-08
IL152020A0 (en) 2003-04-10
US6696431B2 (en) 2004-02-24

Similar Documents

Publication Publication Date Title
ATE374178T1 (de) 2-alkylidene-19-nor-vitamin d verbindungen und ihre therapeutische verwendungen
ATE223890T1 (de) 2-alkyliden-19-nor-vitamin d-verbindungen
ATE253046T1 (de) 2-alkyl-19-nor-vitamin d-verbindungen
CA2403232A1 (en) 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds
MXPA04005456A (es) Derivados de acetileno que tienen actividad antagonistica de mglur5.
TW200407320A (en) Macrocyclic compounds useful as pharmaceuticals
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
TNSN04199A1 (en) Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
ATE411296T1 (de) Imidazolinderivate mit cb1-antagonistischer wirkung
PL376324A1 (en) Piperazinyl and diazapanyl benzamides and benzthioamides
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
ATE282605T1 (de) 2-thio-subsituierte imidazolderivative und ihre verwendung in der pharmazie
DE602005018203D1 (de) Arylalkylsulfonamide als therapeutische mittel zur behandlung von knochenleiden
CY1107362T1 (el) Παραγωγα ιμιδαζολυλιου χρησιμα ως συνδετες υποδοχεων ισταμινης h3
ATE517626T1 (de) Aminosubstituierte sulphonanilide und ihre derivate zur behandlung von proliferativen erkrankungen
RS88704A (en) Acyl-3-carboxyphenylurea derivatives, method for production and use thereof
MXPA04001855A (es) Derivados de sistemas de indan-1-ol c2-sustituidos, metodos para la produccion de los mismos y su uso como medicamentos.
ATE350043T1 (de) 2-methylen-19-nor-20(s)-25-methyl-1alpha- hydroxycalciferol und seine verwendungen
TH62500A (th) Nk1 แอนทาโกนิสท์

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1268416

Country of ref document: EP